Know Cancer

forgot password

Radiofrequency Ablation of Pulmonary Malignancy

Phase 2
Not Enrolling
Lung Cancer, Malignant Mesothelioma, Metastatic Cancer, Thymoma and Thymic Carcinoma

Thank you

Trial Information

Radiofrequency Ablation of Pulmonary Malignancy


- Determine the safety and toxicity of radiofrequency ablation in patients with
refractory or advanced pulmonary malignancies.

- Determine the efficacy of this treatment, in terms of local control, in these patients.

- Determine whether CT scan is a reasonable imaging assessment tool for treatment
delivery and follow-up in these patients.

OUTLINE: Patients undergo percutaneous CT-guided radiofrequency ablation directly to the
tumor over 2 hours.

Patients are followed at 1, 3, 6, and 12 months.

PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.

Inclusion Criteria:

- Diagnosis of a primary or secondary intrathoracic malignancy

- Any cell type or origin

- Involving the intrapulmonary, mediastinal, or pleural/chest wall

- Inoperable primary or metastatic cancer to the lung

- Refractory to or not amenable to conventional therapy (e.g., surgery, chemotherapy,
or radiotherapy)

- Single or multiple lesions that are non-contiguous with vital structures or organs
such as:

- Trachea

- Heart

- Aorta

- Great vessels

- Esophagus

- Less than 5 cm in largest dimension

- Accessible via percutaneous transthoracic route

- Hepatic:

- Coagulation profile normal

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Principal Investigator

Robert D. Suh, MD

Investigator Role:

Study Chair

Investigator Affiliation:

Jonsson Comprehensive Cancer Center


United States: Federal Government

Study ID:




Start Date:

May 2000

Completion Date:

Related Keywords:

  • Lung Cancer
  • Malignant Mesothelioma
  • Metastatic Cancer
  • Thymoma and Thymic Carcinoma
  • recurrent non-small cell lung cancer
  • recurrent small cell lung cancer
  • recurrent malignant mesothelioma
  • recurrent thymoma and thymic carcinoma
  • stage IIIB non-small cell lung cancer
  • stage IV non-small cell lung cancer
  • pulmonary carcinoid tumor
  • lung metastases
  • Carcinoma
  • Lung Neoplasms
  • Mesothelioma
  • Neoplasm Metastasis
  • Neoplasms
  • Neoplasms, Second Primary
  • Thymoma



Jonsson Comprehensive Cancer Center, UCLA Los Angeles, California  90095-1781